However, further therapeutic approaches like blocking mAbs, bispecific mAbs, chimeric-antigen receptor (CAR) T-cells, small molecule inhibitors, and synergistic options (chemo/radiation/ anti-CTLA4/anti-PD-1 together with anti-B7-H3) need to be evaluated in targeting B7-H3 for different cancers, including PBTs. This evidence concerns the gene CD276 and cancer.